Liquid Biopsy Intelligence: Integrating Circulating Biomarkers, Multi-Omics, and AI for Early Cancer Detection

Abstract

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. Early cancer detection remains one of the mosteffective strategies for improving patient survival, reducing treatment complexity, and enhancing long-term clinical outcomes.Conventional tissue biopsy, although considered the diagnostic gold standard, is invasive, may not adequately capture tumor heterogeneity, and often cannot be repeated frequently for longitudinal disease monitoring. Recent advances in liquid biopsy technologies have transformed precision oncology by enabling minimally invasive detection of circulating tumor-derived biomarkers including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles, exosomes, circulating RNA, proteins, metabolites, and tumor-educated platelets. Artificial intelligence (AI), multimodal learning, machine learning, deep learning, graph neural networks, transformer architectures, and foundation models have substantially enhanced interpretation of these highly complex circulating biomarker datasets by integrating liquid biopsy with multi-omics, radiological imaging, digital pathology, laboratory biomarkers, and longitudinal clinical information. These intelligent computational systems support early cancer detection, molecular characterization, prognostic prediction, treatment monitoring, minimal residual disease assessment, therapeutic optimization, and recurrence surveillance. Despite remarkable technological progress, important challenges remain regarding assay standardization, analytical sensitivity, computational scalability, explainability, regulatory validation, interoperability, and equitable implementation. This review provides a comprehensive overview of liquid biopsy intelligence in precision oncology, emphasizing computational principles, clinical applications, emerging innovations, and future perspectives for AI-driven early cancer detection.[1]